<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Organophosphate and carbamate poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Organophosphate and carbamate poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Organophosphate and carbamate poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Bird, MD, FACEP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Organophosphates and carbamates are potent cholinesterase inhibitors capable of causing severe cholinergic toxicity following cutaneous exposure, inhalation, or ingestion. Although structurally distinct (<a class="graphic graphic_figure graphicRef57527" href="/z/d/graphic/57527.html" rel="external">figure 1</a>), organophosphates and carbamates exhibit similar clinical manifestations with toxicity and require similar management following overdose.</p><p>An overview of organophosphate and carbamate poisoning will be presented here. A summary table to facilitate emergent management is provided (<a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">table 1</a>). A general approach to suspected drug intoxication is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="headingAnchor" id="H12153918"><span class="h1">EPIDEMIOLOGY AND SOURCES OF EXPOSURE</span><span class="headingEndMark"> — </span>Organophosphates have been used as insecticides worldwide for more than 50 years. The use of these agents has declined in the last 10 to 20 years, in part due to the development of carbamate insecticides, which are associated with similar toxicities [<a href="#rid1">1</a>]. Medical applications of organophosphates and carbamates include reversal of neuromuscular blockade (<a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">neostigmine</a>, <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a>, <a class="drug drug_general" data-topicid="9403" href="/z/d/drug information/9403.html" rel="external">edrophonium</a>) and treatment of glaucoma, myasthenia gravis, and Alzheimer disease (<a class="drug drug_general" data-topicid="9398" href="/z/d/drug information/9398.html" rel="external">echothiophate</a>, pyridostigmine, tacrine, and <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">donepezil</a>).</p><p>Worldwide, an estimated 3,000,000 people are exposed to organophosphate or carbamate agents each year, with up to 300,000 fatalities [<a href="#rid2">2-4</a>]. In the United States, there were more than 8000 reported exposures to these agents in 2008, resulting in fewer than 15 deaths [<a href="#rid5">5</a>]. Toxicity generally results from accidental or intentional ingestion of, or exposure to, agricultural pesticides [<a href="#rid2">2,4,6</a>]. Other potential causes of organophosphate or carbamate toxicity include ingestion of contaminated fruit, flour, or cooking oil, and wearing contaminated clothing [<a href="#rid6">6,7</a>]. </p><p>Specific agents linked to human poisoning include both carbamate (methomyl and aldicarb) and organophosphate (parathion, fenthion, <a class="drug drug_general" data-topicid="9584" href="/z/d/drug information/9584.html" rel="external">malathion</a>, diazinon, and dursban) insecticides. Chlorpyrifos, the organophosphate agent of dursban, is found in some popular household roach and ant sprays, including Raid and Black Flag (<a class="graphic graphic_figure graphicRef74088" href="/z/d/graphic/74088.html" rel="external">figure 2</a>). The United States Environmental Protection Agency (EPA) banned many household uses of chlorpyrifos in 2001, and has restricted its use on certain crops including tomatoes, apples, and grapes [<a href="#rid8">8</a>].</p><p>Several organophosphorus nerve agents (eg, tabun [GA], sarin [GB], soman [GD]) were developed in Germany during the 1940s, but were not used for military purposes [<a href="#rid9">9</a>]. The 1995 sarin attack on the Tokyo subway system by the religious cult Aum Shinrikyo and subsequent international events have heightened awareness regarding the prevention, recognition, and treatment of casualties due to organophosphorus ("nerve") agent exposure [<a href="#rid10">10-12</a>]. More recently, assassination attempts involving Novichok, a newer class of organophosphorus nerve agent that also affects peripheral nerves, have been perpetrated in Europe [<a href="#rid13">13-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2020.html" rel="external">"Chemical terrorism: Rapid recognition and initial medical management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Organophosphorus compounds contain carbon and phosphorous acid derivatives (<a class="graphic graphic_figure graphicRef57527" href="/z/d/graphic/57527.html" rel="external">figure 1</a>). These agents are well absorbed through the skin, lungs, and gastrointestinal tract. They bind to acetylcholinesterase (AChE), also known as red blood cell (RBC) acetylcholinesterase, and render this enzyme non-functional. AChE is the enzyme responsible for hydrolysis of acetylcholine to choline and acetic acid, and inhibition leads to an overabundance of acetylcholine at the neuronal synapses and the neuromuscular junction [<a href="#rid16">16,17</a>].</p><p>After some period of time (dependent on the chemical structure of the organophosphorus agent), the acetylcholinesterase-organophosphorus compound undergoes a conformational change, known as "aging," which renders the enzyme <strong>irreversibly</strong> resistant to reactivation by an antidotal oxime (<a class="graphic graphic_figure graphicRef78828" href="/z/d/graphic/78828.html" rel="external">figure 3</a>) [<a href="#rid18">18</a>].</p><p>In addition, plasma cholinesterase (also called butylcholinesterase [BuChE] or pseudocholinesterase) and neuropathy target esterase (NTE) are inhibited by organophosphorus agents; however, the clinical significance of these interactions are less certain [<a href="#rid19">19,20</a>].</p><p>Carbamate compounds are derived from carbamic acid (<a class="graphic graphic_figure graphicRef57527" href="/z/d/graphic/57527.html" rel="external">figure 1</a>). Like organophosphorus agents, carbamates are rapidly absorbed via all routes of exposure. Unlike organophosphates, these agents are <strong>transient</strong> cholinesterase inhibitors, which spontaneously hydrolyze from the cholinesterase enzymatic site within 48 hours. Carbamate toxicity tends to be of shorter duration than that caused by equivalent doses of organophosphates, although the mortality rates associated with exposure to these chemical classes are similar [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Onset and duration of AChE inhibition varies depending on the organophosphorus agent's rate of AChE inhibition, the route of absorption, enzymatic conversion to active metabolites, and the lipophilicity of the organophosphorus agent. For most agents, oral or respiratory exposures generally result in signs or symptoms within three hours, while symptoms of toxicity from dermal absorption may be delayed up to 12 hours. Lipophilic agents such as dichlofenthion, fenthion, and <a class="drug drug_general" data-topicid="9584" href="/z/d/drug information/9584.html" rel="external">malathion</a> are associated with delayed onset of symptoms (up to five days) and prolonged illness (greater than 30 days), which may be related to rapid adipose fat uptake and delayed redistribution from the fat stores (<a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">table 1</a>). The great variability in toxicity and treatment response among organophosphorus agents, however, is not well understood, leading some to suggest that each agent be considered independently in future studies [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Acute toxicity</span></p><p class="headingAnchor" id="H38210922"><span class="h3">Cholinergic excess</span><span class="headingEndMark"> — </span>Acute toxicity from organophosphorus agents presents with manifestations of cholinergic excess. Primary toxic effects involve the autonomic nervous system, neuromuscular junction, and central nervous system (CNS) [<a href="#rid22">22</a>]. The parasympathetic nervous system is particularly dependent on acetylcholine regulation, since both the autonomic ganglia and end organs of the parasympathetic nervous system are regulated by nicotinic and muscarinic cholinergic receptor subtypes, respectively (<a class="graphic graphic_figure graphicRef75227" href="/z/d/graphic/75227.html" rel="external">figure 4</a>).</p><p>The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea. Diaphoresis occurs because sweat glands are regulated through sympathetic activation of postganglionic muscarinic receptors. At times, however, mydriasis and tachycardia may be observed, as sympathetic ganglia also contain nicotinic receptors (<a class="graphic graphic_figure graphicRef75227" href="/z/d/graphic/75227.html" rel="external">figure 4</a>).</p><p>The muscarinic signs can be remembered by use of one of two mnemonics:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SLUDGE/BBB</strong> – <strong>S</strong>alivation, <strong>L</strong>acrimation, <strong>U</strong>rination, <strong>D</strong>efecation, <strong>G</strong>astric <strong>E</strong>mesis, <strong>B</strong>ronchorrhea, <strong>B</strong>ronchospasm, <strong>B</strong>radycardia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DUMBELS</strong> – <strong>D</strong>efecation, <strong>U</strong>rination, <strong>M</strong>iosis, <strong>B</strong>ronchorrhea/Bronchospasm/Bradycardia, <strong>E</strong>mesis, <strong>L</strong>acrimation, <strong>S</strong>alivation [<a href="#rid23">23</a>]</p><p></p><p>It should be noted that these mnemonics do <strong>NOT</strong> take into account the critical CNS and nicotinic effects of these toxins. The nicotinic effects include fasciculations, muscle weakness, and paralysis via acetylcholine stimulation of receptors at the neuromuscular junction. This mechanism is analogous to the depolarizing effects of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> in producing neuromuscular blockade. Nicotinic and muscarinic receptors also have been identified in the brain, and may contribute to central respiratory depression, lethargy, seizures, and coma (<a class="graphic graphic_figure graphicRef75227" href="/z/d/graphic/75227.html" rel="external">figure 4</a>).</p><p class="headingAnchor" id="H38210940"><span class="h3">Cardiac issues</span><span class="headingEndMark"> — </span>Cardiac arrhythmias, including heart block and QTc prolongation, are occasionally observed in organophosphorus agent poisoning [<a href="#rid24">24</a>]. It is unclear whether these arrhythmias are due to direct toxicity or secondary hypoxemia. </p><p>Case reports and small case series suggest that up to one-third of patients with severe OP poisoning manifest signs of myocardial ischemia, such as an elevated troponin or changes in the electrocardiogram (ECG) [<a href="#rid25">25,26</a>]. Peak troponin concentrations occur at presentation in most cases. Risk appears to be greatest in older patients and those with severe poisoning, but low in patients with mild poisoning. (See  <a class="medical medical_review" href="/z/d/html/2095.html" rel="external">"Electrocardiogram in the diagnosis of myocardial ischemia and infarction"</a>.)</p><p class="headingAnchor" id="H38210934"><span class="h3">Respiratory issues</span><span class="headingEndMark"> — </span>Fatalities from acute organophosphorus agent poisoning generally result from respiratory failure due to a combination of depression of the CNS respiratory center, neuromuscular weakness, excessive respiratory secretions, and bronchoconstriction. Fatalities also occur due to cardiovascular collapse; although the mechanism of this dysfunction is not completely understood, inappropriate vasodilation may play a role [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Intermediate (neurologic) syndrome</span><span class="headingEndMark"> — </span>Ten to 40 percent of patients poisoned with organophosphorus develop a distinct neurologic disorder 24 to 96 hours after exposure and resolution of cholinergic excess. This disorder, referred to as the "intermediate syndrome," consists of characteristic neurological findings including neck flexion weakness, decreased deep tendon reflexes, cranial nerve abnormalities, proximal muscle weakness, and respiratory insufficiency [<a href="#rid28">28-30</a>].</p><p>Risk factors for the development of intermediate syndrome appear to include exposure to a highly fat-soluble organophosphorus agent, and may be related to inadequate doses of oximes [<a href="#rid31">31</a>]. The intermediate syndrome has rarely been described following carbamate poisoning.</p><p>With adequate supportive care, including prolonged mechanical ventilation, most patients have complete resolution of neurologic dysfunction within two to three weeks. Clinical deterioration and improvement appear to correlate with red blood cell (RBC) acetylcholinesterase levels. Nerve conduction studies on patients with intermediate syndrome reveal unique postsynaptic abnormalities that differentiate this disorder from delayed neurotoxicity (see <a class="local">'Delayed and long-term neuropathology'</a> below) [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/5277.html" rel="external">"Evaluation of peripheral nerve and muscle disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Delayed and long-term neuropathology</span><span class="headingEndMark"> — </span>Organophosphorus agent induced delayed neuropathy (OPIDN) typically occurs one to three weeks after ingestion of one of a small number of specific organophosphorus agents, including chlorpyrifos (<a class="graphic graphic_figure graphicRef66967" href="/z/d/graphic/66967.html" rel="external">figure 5</a>) [<a href="#rid33">33-35</a>]. Carbamates are only rarely associated with the development of OPIDN [<a href="#rid36">36,37</a>]. The mechanism may involve inhibition of neuropathy target esterase (NTE), rather than alterations in RBC acetylcholinesterase function (see <a class="local">'Mechanism of action'</a> above) [<a href="#rid38">38</a>]. This enzyme, which is found in the brain, peripheral nerves, and lymphocytes, is responsible for the metabolism of various esters within the cell.</p><p>Affected patients present with transient, painful "stocking-glove" paresthesias followed by a symmetrical motor polyneuropathy characterized by flaccid weakness of the lower extremities, which ascends to involve the upper extremities. Sensory disturbances are usually mild. Delayed neurotoxicity primarily affects distal muscle groups, but in severe neurotoxicity, proximal muscles groups may also be affected [<a href="#rid39">39</a>]. Electromyograms and nerve conduction studies of affected patients reveal decreased firing of motor conduction units [<a href="#rid40">40</a>]. Histopathologic sections of peripheral nerves reveal Wallerian (or "dying-back") degeneration of large distal axons [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/5277.html" rel="external">"Evaluation of peripheral nerve and muscle disease"</a>.)</p><p>The risk of developing OPIDN is <strong>independent</strong> of the severity of acute cholinergic toxicity. Some organophosphorus agents, such as parathion, are potent cholinergic agents but are not associated with OPIDN. Others, such as triorthocresyl phosphate (TOCP), produce few clinical signs of cholinergic excess but are frequently implicated in OPIDN (<a class="graphic graphic_figure graphicRef66967" href="/z/d/graphic/66967.html" rel="external">figure 5</a>) [<a href="#rid42">42</a>]. Most cases of mild delayed neurotoxicity improve with time; in severe cases, an upper motor neuron syndrome with spasticity of the lower extremities usually causes permanent disability.</p><p>Survivors of acute organophosphorus agent poisoning may have neurobehavioral deficits such as decreased memory, abstraction, and attention, and Parkinsonism, which may be permanent [<a href="#rid43">43-45</a>]. It is unclear if these neurocognitive effects are due to direct neurotoxicity of organophosphorus agents themselves, or related to hypoxia and other non-specific effects of serious illness.</p><p class="headingAnchor" id="H101528008"><span class="h2">Additional effects</span><span class="headingEndMark"> — </span>Several case reports describe acute kidney injury (AKI) requiring renal replacement therapy in the setting of severe organophosphate poisoning [<a href="#rid46">46,47</a>]. Causality has not been established and it remains unclear whether the AKI is due directly to the OP or the general effects of critical illness, but in severe OP poisoning it is prudent to monitor renal function. Acute pancreatitis may complicate poisoning caused by either organophosphates or carbamates [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H8"><span class="h2">Clinical findings</span><span class="headingEndMark"> — </span>The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds. In the absence of a known ingestion or exposure, the clinical features of cholinergic excess should indicate the possibility of organophosphate poisoning. Many organophosphorus agents have a characteristic petroleum or garlic-like odor, which may be helpful in establishing the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p>Due to significant variability in toxicity, every effort should be made to precisely identify the agent. It is imperative to determine if a dimethyl or a diethyl poison was involved (<a class="graphic graphic_figure graphicRef57527" href="/z/d/graphic/57527.html" rel="external">figure 1</a>). The duration of toxicity and the therapeutic window during which oxime treatment is likely to be effective are markedly different for these two classes of toxins. Dimethyl compounds undergo rapid aging, making early initiation of oxime therapy critical; diethyl compounds may exhibit delayed toxicity, and may require prolonged treatment [<a href="#rid3">3</a>].</p><p>If doubt exists as to whether an organophosphate or carbamate has been ingested, a trial of 1 mg <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> in adults (or 0.01 to 0.02 mg/kg in children) may be employed. The absence of signs or symptoms of anticholinergic effects following atropine challenge strongly supports the diagnosis of poisoning with an acetylcholinesterase inhibitor.</p><p class="headingAnchor" id="H9"><span class="h2">Laboratory abnormalities</span><span class="headingEndMark"> — </span>Direct measurement of RBC acetylcholinesterase (RBC AChE) activity provides a measure of the degree of toxicity. Sequential measurement of RBC AChE activity (if rapidly available) may also be used to determine the effectiveness of oxime therapy in regeneration of the enzyme. Determination of RBC AChE activity can also be helpful in evaluating chronic or occupational exposure. However, most hospital laboratories are unable to perform this test. An assay for plasma (or pseudo-) cholinesterase activity is more easily performed, but does not correlate well with severity of poisoning and should not be used to guide therapy [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H11"><span class="h2">Initial resuscitation</span><span class="headingEndMark"> — </span>Patients with markedly depressed mental status require 100 percent oxygen and immediate endotracheal intubation. Furthermore, poisoned patients may rapidly develop respiratory failure due to a combination of CNS respiratory center depression, nicotinic receptor mediated diaphragmatic weakness, bronchospasm, and copious secretions. Thus, even patients with normal mental status or normal vital signs may require early endotracheal intubation. A summary table to facilitate emergent management is provided (<a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">table 1</a>).</p><p>Clinicians should avoid the use of <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> when performing rapid sequence intubation (RSI) in patients with organophosphate (OP) poisoning. Succinylcholine is metabolized by acetylcholinesterase (which is inhibited by OP compounds) leading to exaggerated and prolonged neuromuscular blockade in poisoned patients. Nondepolarizing neuromuscular blocking agents (eg, <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">rocuronium</a>) can be used, but may be less effective at standard doses due to competitive inhibition at the neuromuscular junction. Therefore, increased doses will likely be needed. (See  <a class="medical medical_review" href="/z/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.)</p><p>Bradycardia and hypotension are usually present in moderate to severe poisonings. However, tachycardia or hypertension may transiently occur due to direct sympathetic stimulation. Adequate volume resuscitation with isotonic crystalloid (eg, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a> solution) should be performed concomitantly with other resuscitative and diagnostic efforts. (See  <a class="medical medical_review" href="/z/d/html/1594.html" rel="external">"Definition, classification, etiology, and pathophysiology of shock in adults"</a>.)</p><p class="headingAnchor" id="H38211064"><span class="h2">Cholinergic toxicity</span><span class="headingEndMark"> — </span>Patients with cholinergic toxicity due to organophosphate or carbamate poisoning are treated with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> and oxime therapy (typically <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">pralidoxime</a>) as described below.</p><p class="headingAnchor" id="H12"><span class="h3">Atropine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> competes with acetylcholine at muscarinic receptors, preventing cholinergic activation. For moderate to severe cholinergic toxicity, atropine should be administered beginning at a dose of 2 to 5 mg IV for adults and 0.05 mg/kg IV for children. If no effect is noted, the dose should be doubled every three to five minutes until pulmonary muscarinic signs and symptoms are alleviated. It is not necessary to provide oxygen prior to initiating treatment with atropine [<a href="#rid50">50</a>].</p><p><a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> dosing should be titrated to the therapeutic end point of the clearing of respiratory secretions and the cessation of bronchoconstriction [<a href="#rid51">51</a>]. Tachycardia and mydriasis are <strong>not</strong> appropriate markers for therapeutic improvement, as they may indicate continued hypoxia, hypovolemia, or sympathetic stimulation. In patients with severe poisoning, <strong>hundreds</strong> of milligrams of atropine by bolus and continuous infusion may be required over the course of several days. For patients who do not respond to high doses of atropine, clinicians may add treatment with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. (See <a class="local">'Epinephrine'</a> below.)</p><p>In patients with moderate or severe toxicity, after desired response is achieved with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> by bolus, we administer 10 to 20 percent of the total cumulative bolus dose as an IV continuous infusion per hour [<a href="#rid52">52-54</a>]. We adjust the infusion rate as needed to maintain adequate response (eg, clear lung auscultation, heart rate &gt;80 beats/minute, systolic blood pressure &gt;80 mmHg, dry axilla, pupils no longer pinpoint) without causing atropine toxicity (eg, confusion, pyrexia, absent bowel sounds, urinary retention). We adjust the infusion according to clinical response and taper until recovery. When atropine toxicity occurs, we hold the infusion until toxicity resolves and restart at 70 to 80 percent of the previous infusion rate.</p><p>This individualized approach to treatment is supported by the results of an open label randomized trial in which patients (n = 156) treated with incremental doses of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> plus infusion experienced lower mortality (6 versus 18 deaths) and fewer episodes of atropine toxicity than patients treated with a standard bolus dose plus infusion [<a href="#rid52">52</a>]. </p><p>In June 2003, the United States Food and Drug Administration (FDA) approved pediatric doses of Atropen (<a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> autoinjector) for children and adolescents exposed to certain nerve agents and pesticides [<a href="#rid55">55</a>]. Atropen is designed for acute use by nonphysicians trained in the recognition and treatment of nerve agent or insecticide intoxication. The approved doses for mild symptoms of nerve agent poisoning vary by weight, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>15 to 40 pounds (7 to 18 kg): 0.5 mg</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;40 to 90 pounds (&gt;18 to 41 kg): 1.0 mg</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;90 pounds and adults (&gt;41 kg): 2.0</p><p></p><p>Up to three times these doses may be administered to children with acute symptoms of severe nerve agent poisoning.</p><p class="headingAnchor" id="H3897377946"><span class="h3">Epinephrine</span><span class="headingEndMark"> — </span>A relatively small percentage of patients do not respond adequately to high-dose <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> therapy and may require treatment with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. Little evidence is available to guide such decisions. The author would initiate an epinephrine infusion for patients whose heart rate remains below 80 beats per minute (bpm) or who remains hypotensive with an adequate heart rate (eg, 80 to 100 bpm) despite receiving high doses of atropine. </p><p>In a clinical trial of 155 patients treated for organophosphate poisoning, 21 (13.6 percent) did not mount a heart rate of at least 100 bpm despite high-dose <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> therapy and were additionally treated with an <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> infusion. All patients treated with epinephrine had an increase in heart rate, with 14 (75 percent) able to meet a prespecified goal of 100 bpm. Most patients needed epinephrine for less than 12 hours, and all patients were successfully weaned off epinephrine within 24 hours. Given limitations of the study design, no mortality benefits were evident with the addition of epinephrine.</p><p class="headingAnchor" id="H13"><span class="h3">Pralidoxime</span><span class="headingEndMark"> — </span>Since <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> does not bind to nicotinic receptors, it is ineffective in treating neuromuscular dysfunction. <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">Pralidoxime</a> (2-PAM) and other oximes, such as HI-6 and obidoxime, are cholinesterase reactivating agents that are effective in treating both muscarinic and nicotinic symptoms (<a class="graphic graphic_figure graphicRef78828" href="/z/d/graphic/78828.html" rel="external">figure 3</a>) [<a href="#rid3">3,17,56</a>]. Pralidoxime should <strong>not</strong> be administered without concurrent atropine in order to prevent worsening symptoms due to transient oxime-induced acetylcholinesterase inhibition [<a href="#rid57">57</a>].</p><p>We suggest that oxime therapy be given to all patients with evidence of cholinergic toxicity, patients with neuromuscular dysfunction, or patients with exposures to organophosphorus agents known to cause delayed neurotoxicity (<a class="graphic graphic_figure graphicRef66967" href="/z/d/graphic/66967.html" rel="external">figure 5</a>). The current World Health Organization recommendation for IV bolus therapy with <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">pralidoxime</a> is at least 30 mg/kg in adults, and 25 to 50 mg/kg for children, based upon the severity of symptoms [<a href="#rid18">18,58</a>]. Although no treatments have been shown to prevent the intermediate syndrome or organophosphorus agent-induced delayed neuropathy (OIDN), early oxime treatment may be of benefit in this situation [<a href="#rid59">59</a>].</p><p><a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">Pralidoxime</a> should be administered slowly over 30 minutes, since rapid administration has occasionally been associated with cardiac arrest, and slow administration prevents the muscle weakness that results from the transient inhibition of acetylcholinesterase as pralidoxime binds to the enzyme [<a href="#rid60">60</a>]. After the bolus dose, it appears that superior antidotal effects occur with pralidoxime given as a continuous infusion of at least 8 mg/kg per hour in adults and 10 to 20 mg/kg per hour for children [<a href="#rid58">58,61</a>].</p><p>Severe poisonings may result in prolonged redistribution of toxin; therefore, continuous IV therapy should be adjusted based upon the patient's clinical response, and several days of therapy may be required [<a href="#rid62">62</a>]. If rapidly available, serial red blood cell acetylcholinesterase (RBC AChE) concentrations may be valuable in determining the efficacy of oxime-induced acetylcholinesterase regeneration.</p><p>Evidence about the use of oximes to treat OP poisoning is inconsistent and difficult to interpret [<a href="#rid63">63</a>]. There appears to be great variability among victims of organophosphorus poisoning in their clinical response to <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">pralidoxime</a>, which is not well understood. In one large, prospective study, patients poisoned with diethyl compounds (eg, chlorpyrifos) had significantly lower mortality and intubation rates following treatment with pralidoxime than those poisoned with dimethyl agents (eg, dimethoate, fenthion) [<a href="#rid21">21</a>]. Conversely, in a small, double-blinded randomized trial, no significant benefit, and a trend towards harm, was found in the group treated with pralidoxime compared to patients given placebo, regardless of the type of organophosphate ingested [<a href="#rid64">64</a>]. Until this variability is better understood and other treatments become available, we believe that all patients poisoned with organophosphorus agents should be treated with an oxime.</p><p class="headingAnchor" id="H14"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Organophosphorus agent-induced seizures should be treated with a benzodiazepine. Prophylactic <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> has been shown to decrease neurocognitive dysfunction after organophosphorus agent poisoning [<a href="#rid65">65,66</a>]. This led, in part, to the United States military development of a 10 mg autoinjector of diazepam for use in the setting of chemical attack [<a href="#rid67">67,68</a>]. There is no evidence that <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> has any effect on organophosphorus agent-induced seizures, and this agent is not recommended.</p><p class="headingAnchor" id="H15"><span class="h2">Decontamination</span><span class="headingEndMark"> — </span>In cases of topical exposure with potential dermal absorption, aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas should be performed. The patient's clothes and belongings should be discarded since they absorb organophosphorus agents, and reexposure may occur even after washing. Health care workers must take precautions to avoid accidental exposure, including providing treatment in a well-ventilated area [<a href="#rid11">11,69,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2020.html" rel="external">"Chemical terrorism: Rapid recognition and initial medical management"</a>.)</p><p>We generally do not perform gastric lavage. Nevertheless, some clinicians may elect to do so in patients who present less than one hour following ingestion of an organophosphorus agent, AFTER performing endotracheal intubation and initiating therapy with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> and an oxime. Gastric lavage involves substantial risk of aspiration in patients with increased secretions and decreased mental status, and this intervention has never been shown to decrease morbidity or mortality [<a href="#rid51">51</a>].</p><p>Following initial resuscitation and treatment, we suggest activated charcoal (AC) be given to patients presenting within one hour of an organophosphorus agent or carbamate ingestion. The standard dose is 1 g/kg (maximum dose 50 g). We do not give AC to patients presenting more than one hour following ingestion. Findings from randomized and observational trials suggest that AC given after the first hour provides no benefit to patients with these ingestions [<a href="#rid71">71</a>].</p><p>Forced emesis is <strong>contraindicated</strong> because of the risk of aspiration and seizures. Urinary alkalinization has been suggested, but there is no clear evidence that this intervention improves outcome [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a> and  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a>.)</p><p class="headingAnchor" id="H38211239"><span class="h2">Cardiac complications</span><span class="headingEndMark"> — </span>Cardiac complications are typically not the major morbidity associated with OP poisoning, and management is best focused on treating cholinergic toxicity. Based on limited evidence, we believe it is reasonable to monitor patients with severe poisoning for myocardial ischemia by obtaining serial electrocardiograms and serum troponin concentrations approximately every 8 to 12 hours while the patient’s condition remains critical. Given that many of these cases are managed in resource-limited settings, the appropriate level of monitoring will vary.</p><p>In the setting of OP poisoning, myocardial ischemia appears to stem from non-occlusive disease. Treatment with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is probably safe and prudent. We do not suggest other therapies. Should arrhythmias develop, we suggest standard treatments based on the protocols of Advanced Cardiac Life Support. Note that ventricular tachycardia in the setting of OP poisoning may be related to QTc prolongation and treatment with magnesium is reasonable. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.)</p><p class="headingAnchor" id="H12000085"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In the only prospective study to examine prognostic factors for patients acutely poisoned with OP or carbamate (n = 1365), the authors found that a Glasgow Coma Score (GCS) of less than 13 portends a poor prognosis, and using the GCS was as good as using the International Program on Chemical Safety Poison Severity Score (IPCS PSS) [<a href="#rid73">73</a>]. However, the authors point out that the OP agent involved must be taken into account, as one-half of the fenthion-poisoned patients who died had only mild symptoms at presentation. A retrospective study of nearly 400 OP-poisoned patients examined the performance of several standard ICU-based clinical scoring systems [<a href="#rid74">74</a>]. This study reported that the Acute Physiology and Chronic Health Evaluation II (APACHE-II), Simplified Acute Physiology Score II (SAPS-II), and the Mortality Prediction Model II (MPM-II) scoring systems outperformed the Poisoning Severity Scale in predicting death. Again, however, the performance of these scoring systems was partly dependent upon the OP agent involved. </p><p>Until larger prospective studies can be performed, we suggest using one of the above clinical scoring systems to help determine prognosis, but only for those specific OP-pesticides that were included in the relevant study. Particular attention must be given to patients poisoned with lipophilic OPs such as fenthion and parathion, as these patients may exhibit delayed and prolonged poisoning symptoms.</p><p class="headingAnchor" id="H16"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2795234807"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. </p><p>Further information on pesticide intoxication can be obtained in the United States from National Pesticide Telecommunications Network at: 1-800-858-7378 or <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fnpic.orst.edu%2F&amp;token=ZJX7zTZmR11fCA7HKkEfzEe1uKthBcVxhrJaOJSNDJI%3D&amp;TOPIC_ID=339" target="_blank">http://npic.orst.edu/</a> (outside the United States: 1-806-743-3091).</p><p class="headingAnchor" id="H102545018"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Acute toxicity from organophosphorus agents presents with manifestations of cholinergic excess. The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea. (See <a class="local">'Acute toxicity'</a> above.)</p><p></p><p class="bulletIndent1">Ten to 40 percent of organophosphorus-poisoned patients develop a distinct neurologic disorder 24 to 96 hours after exposure. This disorder consists of characteristic neurological findings including neck flexion weakness, decreased deep tendon reflexes, cranial nerve abnormalities, proximal muscle weakness, and respiratory insufficiency. (See <a class="local">'Intermediate (neurologic) syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds. Organophosphate poisoning should be suspected in a patient with clinical features of cholinergic excess in the absence of a known ingestion or exposure. Due to significant variability in toxicity and treatment, every effort should be made to precisely identify the agent when known. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis can be confirmed by either direct measurement of RBC acetylcholinesterase (RBC AChE) activity or plasma (or pseudo-) cholinesterase activity. Most hospital laboratories are unable to perform the former test, while the latter is more easily performed but does not correlate well with severity of poisoning. Determination of RBC AChE activity can also be helpful in evaluating chronic or occupational exposure. (See <a class="local">'Laboratory abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of management</strong> – All symptomatic patients should receive therapy with oxygen, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>, an oxime (eg, <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">pralidoxime</a>), and a benzodiazepine. The management of these patients may be complex and protracted. A summary table to facilitate emergency management is provided (<a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">table 1</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decontamination</strong> – In cases of topical exposure with potential dermal absorption, aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas should be performed. (See <a class="local">'Decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care and ABCs</strong> – Patients with markedly depressed mental status or respiratory failure require 100% oxygen and immediate tracheal intubation. <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">Succinylcholine</a> should be avoided when performing rapid sequence intubation in patients with organophosphate poisoning. Bradycardia and hypotension are usually present in moderate to severe poisonings. Adequate volume resuscitation with isotonic crystalloid should be performed concomitantly with other resuscitative and diagnostic efforts. (See <a class="local">'Initial resuscitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atropine</strong> – We recommend <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> therapy for all patients with any degree of possible cholinergic toxicity from organophosphate or carbamate poisoning (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Atropine is started at a dose of 2 to 5 mg intravenously (IV) for adults and 0.05 mg/kg IV for children. If no effect is noted, the dose is doubled every three to five minutes until pulmonary muscarinic signs and symptoms are alleviated. (See <a class="local">'Atropine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oxime therapy</strong> – We suggest that oxime therapy (eg, <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">pralidoxime</a>) be given to all patients with evidence of cholinergic toxicity, patients with neuromuscular dysfunction, or patients with exposures to organophosphorus agents known to cause delayed neurotoxicity (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The current World Health Organization recommendation for IV bolus therapy with pralidoxime is at least 30 mg/kg in adults, and 25 to 50 mg/kg for children, based on severity of symptoms, administered slowly over 30 minutes. Pralidoxime should <strong>not</strong> be administered without concurrent <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>. (See <a class="local">'Pralidoxime'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizure treatment </strong>– Organophosphate-induced seizures should be treated with a benzodiazepine. Prophylactic <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> (eg, 10 mg IV) can decrease neurocognitive dysfunction after organophosphate agent poisoning. (See <a class="local">'Seizures'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rotenberg M, Shefi M, Dany S, et al. Differentiation between organophosphate and carbamate poisoning. Clin Chim Acta 1995; 234:11.</a></li><li><a class="nounderline abstract_t">Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ 2004; 328:42.</a></li><li><a class="nounderline abstract_t">Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003; 22:165.</a></li><li><a class="nounderline abstract_t">Karunarathne A, Gunnell D, Konradsen F, Eddleston M. How many premature deaths from pesticide suicide have occurred since the agricultural Green Revolution? Clin Toxicol (Phila) 2020; 58:227.</a></li><li><a class="nounderline abstract_t">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.</a></li><li><a class="nounderline abstract_t">Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.</a></li><li><a class="nounderline abstract_t">Wu ML, Deng JF, Tsai WJ, et al. Food poisoning due to methamidophos-contaminated vegetables. J Toxicol Clin Toxicol 2001; 39:333.</a></li><li class="breakAll">United States Environmental Protection Agency. Organophosphate pesticide information. www.epa.gov/pesticides/op/chlorpyrifos/consumerqs.htm (Accessed on May 03, 2005).</li><li><a class="nounderline abstract_t">Buckley NA, Roberts D, Eddleston M. Overcoming apathy in research on organophosphate poisoning. BMJ 2004; 329:1231.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Recognition of illness associated with exposure to chemical agents--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:938.</a></li><li><a class="nounderline abstract_t">Okudera H, Morita H, Iwashita T, et al. Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first sarin gas terrorism. Am J Emerg Med 1997; 15:527.</a></li><li><a class="nounderline abstract_t">Reutter S. Hazards of chemical weapons release during war: new perspectives. Environ Health Perspect 1999; 107:985.</a></li><li><a class="nounderline abstract_t">Chai PR, Hayes BD, Erickson TB, Boyer EW. Novichok agents: a historical, current, and toxicological perspective. Toxicol Commun 2018; 2:45.</a></li><li><a class="nounderline abstract_t">Steindl D, Boehmerle W, Körner R, et al. Novichok nerve agent poisoning. Lancet 2021; 397:249.</a></li><li><a class="nounderline abstract_t">Vale JA, Marrs TC OBE, Maynard RL CBE. Novichok: a murderous nerve agent attack in the UK. Clin Toxicol (Phila) 2018; 56:1093.</a></li><li><a class="nounderline abstract_t">Tafuri J, Roberts J. Organophosphate poisoning. Ann Emerg Med 1987; 16:193.</a></li><li><a class="nounderline abstract_t">Khurana D, Prabhakar S. Organophosphorus intoxication. Arch Neurol 2000; 57:600.</a></li><li><a class="nounderline abstract_t">Eddleston M, Szinicz L, Eyer P, Buckley N. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM 2002; 95:275.</a></li><li><a class="nounderline abstract_t">Morgan JP. The Jamaica ginger paralysis. JAMA 1982; 248:1864.</a></li><li><a class="nounderline abstract_t">Mutch E, Blain PG, Williams FM. Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol 1992; 11:109.</a></li><li><a class="nounderline abstract_t">Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet 2005; 366:1452.</a></li><li><a class="nounderline abstract_t">Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 1974; 7:1.</a></li><li><a class="nounderline abstract_t">Sidell FR. Clinical effects of organophosphorus cholinesterase inhibitors. J Appl Toxicol 1994; 14:111.</a></li><li><a class="nounderline abstract_t">Wang MH, Tseng CD, Bair SY. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case. Hum Exp Toxicol 1998; 17:587.</a></li><li><a class="nounderline abstract_t">Cha YS, Kim H, Go J, et al. Features of myocardial injury in severe organophosphate poisoning. Clin Toxicol (Phila) 2014; 52:873.</a></li><li><a class="nounderline abstract_t">Vijayakumar S, Fareedullah M, Ashok Kumar E, Mohan Rao K. A prospective study on electrocardiographic findings of patients with organophosphorus poisoning. Cardiovasc Toxicol 2011; 11:113.</a></li><li><a class="nounderline abstract_t">Asari Y, Kamijyo Y, Soma K. Changes in the hemodynamic state of patients with acute lethal organophosphate poisoning. Vet Hum Toxicol 2004; 46:5.</a></li><li><a class="nounderline abstract_t">Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med 1987; 316:761.</a></li><li><a class="nounderline abstract_t">Indira M, Andrews MA, Rakesh TP. Incidence, predictors, and outcome of intermediate syndrome in cholinergic insecticide poisoning: a prospective observational cohort study. Clin Toxicol (Phila) 2013; 51:838.</a></li><li><a class="nounderline abstract_t">Karalliedde L, Baker D, Marrs TC. Organophosphate-induced intermediate syndrome: aetiology and relationships with myopathy. Toxicol Rev 2006; 25:1.</a></li><li><a class="nounderline abstract_t">Groszek B, Pach J, Kłys M. Intermediate syndrome in acute fenitrothion poisoning. Przegl Lek 1995; 52:271.</a></li><li><a class="nounderline abstract_t">De Bleecker J, Van den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med 1993; 21:1706.</a></li><li><a class="nounderline abstract_t">Moretto A, Lotti M. Poisoning by organophosphorus insecticides and sensory neuropathy. J Neurol Neurosurg Psychiatry 1998; 64:463.</a></li><li><a class="nounderline abstract_t">Sevim S, Aktekin M, Dogu O, et al. Late onset polyneuropathy due to organophosphate (DDVP) intoxication. Can J Neurol Sci 2003; 30:75.</a></li><li><a class="nounderline abstract_t">Pannu AK, Bhalla A, Vishnu RI, et al. Organophosphate induced delayed neuropathy after an acute cholinergic crisis in self-poisoning. Clin Toxicol (Phila) 2021; 59:488.</a></li><li><a class="nounderline abstract_t">Yang PY, Tsao TC, Lin JL, et al. Carbofuran-induced delayed neuropathy. J Toxicol Clin Toxicol 2000; 38:43.</a></li><li><a class="nounderline abstract_t">Dickoff DJ, Gerber O, Turovsky Z. Delayed neurotoxicity after ingestion of carbamate pesticide. Neurology 1987; 37:1229.</a></li><li><a class="nounderline abstract_t">Glynn P. Neuropathy target esterase. Biochem J 1999; 344 Pt 3:625.</a></li><li><a class="nounderline abstract_t">Abou-Donia MB. Organophosphorus ester-induced chronic neurotoxicity. Arch Environ Health 2003; 58:484.</a></li><li><a class="nounderline abstract_t">Aygun D, Onar MK, Altintop BL. The clinical and electrophysiological features of a delayed polyneuropathy developing subsequently after acute organophosphate poisoning and it's correlation with the serum acetylcholinesterase. Electromyogr Clin Neurophysiol 2003; 43:421.</a></li><li><a class="nounderline abstract_t">Johnson MK. Organophosphorus esters causing delayed neurotoxic effects: mechanism of action and structure activity studies. Arch Toxicol 1975; 34:259.</a></li><li><a class="nounderline abstract_t">Craig PH, Barth ML. Evaluation of the hazards of industrial exposure to tricresyl phosphate: a review and interpretation of the literature. J Toxicol Environ Health B Crit Rev 1999; 2:281.</a></li><li><a class="nounderline abstract_t">Arima H, Sobue K, So M, et al. Transient and reversible parkinsonism after acute organophosphate poisoning. J Toxicol Clin Toxicol 2003; 41:67.</a></li><li><a class="nounderline abstract_t">Dassanayake TL, Weerasinghe VS, Gawarammana I, Buckley NA. Subacute and chronic neuropsychological sequalae of acute organophosphate pesticide self-poisoning: a prospective cohort study from Sri Lanka. Clin Toxicol (Phila) 2021; 59:118.</a></li><li><a class="nounderline abstract_t">Dassanayake TL, Weerasinghe VS, Gawarammana IB, Buckley NA. Changes of attention-related brain activity over 6 months after acute organophosphate pesticide poisoning: a prospective follow-up study. Clin Toxicol (Phila) 2022; 60:576.</a></li><li><a class="nounderline abstract_t">Cavari Y, Landau D, Sofer S, et al. Organophosphate poisoning-induced acute renal failure. Pediatr Emerg Care 2013; 29:646.</a></li><li><a class="nounderline abstract_t">Agostini M, Bianchin A. Acute renal failure from organophospate poisoning: a case of success with haemofiltration. Hum Exp Toxicol 2003; 22:165.</a></li><li><a class="nounderline abstract_t">Sahin I, Onbasi K, Sahin H, et al. The prevalence of pancreatitis in organophosphate poisonings. Hum Exp Toxicol 2002; 21:175.</a></li><li class="breakAll">Johnson, MK. Mechanisms of and biomarkers for acute and delayed neuropathic effects of organophosphorus esters. In: Use of Biomarkers in Assessing Health and Environmental Impact of Chemical Pollutants. NATO Advanced Study Workshop. June 1-5, 1992, Amaral-Mendes, J, Traviseds, CC (Eds), Plenum Press, Luso, Portugal 1993. p.169.</li><li><a class="nounderline abstract_t">Konickx LA, Bingham K, Eddleston M. Is oxygen required before atropine administration in organophosphorus or carbamate pesticide poisoning? - A cohort study. Clin Toxicol (Phila) 2014; 52:531.</a></li><li><a class="nounderline abstract_t">Eddleston M, Roberts D, Buckley N. Management of severe organophosphorus pesticide poisoning. Crit Care 2002; 6:259.</a></li><li><a class="nounderline abstract_t">Abedin MJ, Sayeed AA, Basher A, et al. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. J Med Toxicol 2012; 8:108.</a></li><li><a class="nounderline abstract_t">Eddleston M, Dawson A, Karalliedde L, et al. Early management after self-poisoning with an organophosphorus or carbamate pesticide - a treatment protocol for junior doctors. Crit Care 2004; 8:R391.</a></li><li><a class="nounderline abstract_t">Roberts DM, Aaron CK. Management of acute organophosphorus pesticide poisoning. BMJ 2007; 334:629.</a></li><li class="breakAll">United States Food and Drug Administration. FDA approves pediatric doses of Atropen. FDA Talk Paper, www.fda.gov/bbs/topics/ANSWERS/2003/ANS01232.html (Accessed on May 03, 2005).</li><li><a class="nounderline abstract_t">Newmark J. Therapy for nerve agent poisoning. Arch Neurol 2004; 61:649.</a></li><li><a class="nounderline abstract_t">Johnson MK, Jacobsen D, Meredith TJ, et al. Evaluation of antidotes for poisoning by organophosphorus pesticides. Emerg Med 2000; 12:22.</a></li><li class="breakAll">World Health Organization. Environmental Health Criteria No 63. Organophosphorus Pesticides: A General Introduction. World Health Organization, Geneva 1986.</li><li><a class="nounderline abstract_t">Holstege CP, Baer AB. Insecticides. Curr Treat Options Neurol 2004; 6:17.</a></li><li><a class="nounderline abstract_t">Schier JG, Hoffman RS. Treatment of sarin exposure. JAMA 2004; 291:182; author reply 182.</a></li><li><a class="nounderline abstract_t">Pawar KS, Bhoite RR, Pillay CP, et al. Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial. Lancet 2006; 368:2136.</a></li><li><a class="nounderline abstract_t">Schexnayder S, James LP, Kearns GL, Farrar HC. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. J Toxicol Clin Toxicol 1998; 36:549.</a></li><li><a class="nounderline abstract_t">Buckley NA, Eddleston M, Li Y, et al. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst Rev 2011; :CD005085.</a></li><li><a class="nounderline abstract_t">Eddleston M, Eyer P, Worek F, et al. Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial. PLoS Med 2009; 6:e1000104.</a></li><li><a class="nounderline abstract_t">McDonough JH Jr, Zoeffel LD, McMonagle J, et al. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res 2000; 38:1.</a></li><li><a class="nounderline abstract_t">Tuovinen K. Organophosphate-induced convulsions and prevention of neuropathological damages. Toxicology 2004; 196:31.</a></li><li class="breakAll">Office of the U.S. Surgeon General. Army's Diazepam Auto-Injector Package Insert. U.S. Army Medical Research and Development Command (MCMR-RCQ-HR) Fort Detrick, Detrick, MD 1997.</li><li><a class="nounderline abstract_t">Capacio BR, Byers CE, Merk KA, et al. Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. Drug Chem Toxicol 2004; 27:95.</a></li><li><a class="nounderline abstract_t">Stacey R, Morfey D, Payne S. Secondary contamination in organophosphate poisoning: analysis of an incident. QJM 2004; 97:75.</a></li><li><a class="nounderline abstract_t">Geller RJ, Singleton KL, Tarantino ML, et al. Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity--Georgia, 2000. J Toxicol Clin Toxicol 2001; 39:109.</a></li><li><a class="nounderline abstract_t">Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008; 371:579.</a></li><li><a class="nounderline abstract_t">Roberts D, Buckley NA. Alkalinisation for organophosphorus pesticide poisoning. Cochrane Database Syst Rev 2005; :CD004897.</a></li><li><a class="nounderline abstract_t">Davies JO, Eddleston M, Buckley NA. Predicting outcome in acute organophosphorus poisoning with a poison severity score or the Glasgow coma scale. QJM 2008; 101:371.</a></li><li><a class="nounderline abstract_t">Peter JV, Thomas L, Graham PL, et al. Performance of clinical scoring systems in acute organophosphate poisoning. Clin Toxicol (Phila) 2013; 51:850.</a></li></ol></div><div id="topicVersionRevision">Topic 339 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7758210" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Differentiation between organophosphate and carbamate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14703547" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Self poisoning with pesticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181665" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of oximes in the management of organophosphorus pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31500467" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How many premature deaths from pesticide suicide have occurred since the agricultural Green Revolution?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028214" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523881" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527224" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Food poisoning due to methamidophos-contaminated vegetables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527224" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Food poisoning due to methamidophos-contaminated vegetables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550429" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Overcoming apathy in research on organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523372" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recognition of illness associated with exposure to chemical agents--United States, 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270397" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first sarin gas terrorism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585902" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hazards of chemical weapons release during war: new perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30003185" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Novichok agents: a historical, current, and toxicological perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33357496" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Novichok nerve agent poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29757015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novichok: a murderous nerve agent attack in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3541700" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768640" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Organophosphorus intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978898" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6750161" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Jamaica ginger paralysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349216" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interindividual variations in enzymes controlling organophosphate toxicity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243090" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4838227" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027505" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical effects of organophosphorus cholinesterase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9821023" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25116419" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Features of myocardial injury in severe organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21336997" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective study on electrocardiographic findings of patients with organophosphorus poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14748407" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Changes in the hemodynamic state of patients with acute lethal organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3029588" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24047461" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence, predictors, and outcome of intermediate syndrome in cholinergic insecticide poisoning: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856766" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Organophosphate-induced intermediate syndrome: aetiology and relationships with myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644694" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intermediate syndrome in acute fenitrothion poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222687" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intermediate syndrome in organophosphorus poisoning: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9576536" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Poisoning by organophosphorus insecticides and sensory neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12619790" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Late onset polyneuropathy due to organophosphate (DDVP) intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33078989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Organophosphate induced delayed neuropathy after an acute cholinergic crisis in self-poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696923" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Carbofuran-induced delayed neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037439" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Delayed neurotoxicity after ingestion of carbamate pesticide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585848" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neuropathy target esterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15259428" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Organophosphorus ester-induced chronic neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14626722" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The clinical and electrophysiological features of a delayed polyneuropathy developing subsequently after acute organophosphate poisoning and it's correlation with the serum acetylcholinesterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/766733" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Organophosphorus esters causing delayed neurotoxic effects: mechanism of action and structure activity studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10596299" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluation of the hazards of industrial exposure to tricresyl phosphate: a review and interpretation of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12645970" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transient and reversible parkinsonism after acute organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32567959" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Subacute and chronic neuropsychological sequalae of acute organophosphate pesticide self-poisoning: a prospective cohort study from Sri Lanka.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904500" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Changes of attention-related brain activity over 6 months after acute organophosphate pesticide poisoning: a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23640144" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Organophosphate poisoning-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12723899" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute renal failure from organophospate poisoning: a case of success with haemofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099618" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The prevalence of pancreatitis in organophosphate poisonings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099618" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The prevalence of pancreatitis in organophosphate poisonings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24810796" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is oxygen required before atropine administration in organophosphorus or carbamate pesticide poisoning? - A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12133188" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Management of severe organophosphorus pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22351300" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15566582" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early management after self-poisoning with an organophosphorus or carbamate pesticide - a treatment protocol for junior doctors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17379909" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Management of acute organophosphorus pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17379909" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of acute organophosphorus pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148139" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Therapy for nerve agent poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of antidotes for poisoning by organophosphorus pesticides</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evaluation of antidotes for poisoning by organophosphorus pesticides</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14664766" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Insecticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722139" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of sarin exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174705" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9776957" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328273" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Oximes for acute organophosphate pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564902" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604601" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15036754" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Organophosphate-induced convulsions and prevention of neuropathological damages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15036754" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Organophosphate-induced convulsions and prevention of neuropathological damages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198070" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747621" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Secondary contamination in organophosphate poisoning: analysis of an incident.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11327219" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity--Georgia, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280328" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674967" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Alkalinisation for organophosphorus pesticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319295" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Predicting outcome in acute organophosphorus poisoning with a poison severity score or the Glasgow coma scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24066733" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Performance of clinical scoring systems in acute organophosphate poisoning.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
